Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Eur J Cancer. 2017 Feb 4;73:61–70. doi: 10.1016/j.ejca.2016.12.011

Table 1.

Patients characteristics

Variable Category Patients (n=137)
n %
Center Amsterdam 44 32
Essen 11 8
Lausanne 10 7
Nantes 6 4
Naples 18 13
New York 40 29
Siena 8 58
Gender Male 76 55
Female 61 45
Age ≤ 40 years 19 14
> 40 years 57 42
> 60 years 31 23
> 70 years 30 22
Median age 58 years
Number of doses 1 7 5
2 8 6
3 18 13
4 104 76
M category (AJJC) M1a 13 10
M1b 25 18
M1c 98 72
Unknown 1 n.c.
Treatment background CA-184–169 (3 or 10 mg/kg) 3 2
Early access program (3 mg/kg) 68 50
Regular prescription (3 mg/kg) 66 48
Best clinical response (irRC) Complete /partial response 34 26
Stable /progressive disease 96 74
Unknown 7 n.c.